Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
| ▸ | ACE | P12821 | 3/20 | 0.51 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.50 |
| ▸ | TACR3 | P29371 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | NMBR | P28336 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29982992 | 0.90 | CTSL (0.52) | CTSLCTSSCTSKACEKCNT1 | |
| SCHEMBL7090474 | 0.86 | MAPT (0.67) | CTSLCTSSCTSKACEKCNT1 | |
| SCHEMBL6307157 | 0.86 | MAPT (0.67) | CTSLCTSSCTSKACEKCNT1 | |
| SCHEMBL28880633 | 0.86 | KMT2A (0.60) | ACEMAPTKMT2AALOX15 | |
| SCHEMBL6299882 | 0.83 | ACE (0.62) | ACEMAPTLMNAKMT2AALOX15 | |
| SCHEMBL8556329 | 0.83 | ACE (0.62) | ACEMAPTLMNAKMT2AALOX15 | |
| SCHEMBL7834723 | 0.83 | ACE (0.62) | ACEMAPTLMNAKMT2AALOX15 | |
| SCHEMBL8556324 | 0.83 | ACE (0.62) | ACEMAPTLMNAKMT2AALOX15 | |
| SCHEMBL8530746 | 0.83 | ACE (0.62) | ACEMAPTLMNAKMT2AALOX15 | |
| SCHEMBL8530732 | 0.83 | ACE (0.62) | ACEMAPTLMNAKMT2AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119838022-A | Amatoxin conjugates containing branched linkers | 杭州多禧生物科技有限公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-113423430-B | Amatoxin conjugates containing branched linkers | 杭州多禧生物科技有限公司 | 2024-12-03 | — | — | CN | disclosed |
| US-20230057350-A1 | A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-02-23 | — | — | US | disclosed |
| CN-109689107-B | Derivatives of amatoxins and their coupling to cell binding molecules | 杭州多禧生物科技有限公司 | 2022-08-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230057350-A1 | A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS | BTN3A1, ANTXR2, CLTA | CTSL 2022/4885CTSS 3506/4885CTSK 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.